13-LUN-92-CRAB (10-001) Phase I study of mTOR inhibition in NSCLC

Confidential Human Clinical Trial Study objectives 13-LUN-92-CRAB (10-001) Phase I study of mTOR inhibition in NSCLC PI: Dennie V. Jones, MD Primary • To define the Maximum Tolerated Dose (MTD) and Recommended Phase Two Dose (RPTD) of the combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with Stage IV non-squamous NSCLC. Secondary • To describe the safety profile of everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC. • To describe any antitumor efficacy associated with administration of everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC. • To assess the suitability of the MTD as the RTPD in patients with Stage IV non-squamous NSCLC